Figure 2
From: Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
Eight-hour studies with glucagon-like peptide 1. Plasma glucose, pancreatic polypeptide(HPP), incremental glucagon, free immunoreactive insulin, and lactate responses to breakfast and lunch with subcutaneous injection of 0.63 μg/kg GLP-1 (closed circles) or vehicle (open circles) immediately before meals in volunteers with type 1 diabetes, n = 9.